These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 23564832)

  • 1. Usefulness of circulating tumor cells after preliminary chemotherapy for prediction of response to further anticancer therapy in patients with initially unresectable metastatic colorectal cancer.
    Neki K; Kawahara H; Watanabe K; Toyama Y; Akiba T; Yanaga K
    Anticancer Res; 2013 Apr; 33(4):1769-72. PubMed ID: 23564832
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Determination of circulating tumor cells for prediction of recurrent colorectal cancer progression.
    Kawahara H; Watanabe K; Toyama Y; Yanagisawa S; Kobayashi S; Yanaga K
    Hepatogastroenterology; 2012 Oct; 59(119):2115-8. PubMed ID: 22328299
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Usefulness of monthly chemotherapy for patients with unresectable metastatic colorectal cancer.
    Tomoda M; Kawahara H; Watanabe K; Enomoto H; Akiba T; Yanaga K
    Anticancer Res; 2014 Jan; 34(1):191-4. PubMed ID: 24403461
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Feasibility study of oxaliplatin with oral S-1 or capecitabine as first-line therapy for patients with metastases from colorectal cancer.
    Watanabe K; Kawahara H; Enomoto H; Toyama Y; Akiba T; Yanaga K
    Anticancer Res; 2013 Sep; 33(9):4029-32. PubMed ID: 24023346
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of chemotherapy with S-1 and oxaliplatin (SOX) in combination with molecular-targeting agents on colorectal liver metastases.
    Watanabe K; Kawahara H; Enomoto H; Toyama Y; Akiba T; Yanaga K
    Anticancer Res; 2013 Sep; 33(9):3941-6. PubMed ID: 24023332
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A multimarker panel for circulating tumor cells detection predicts patient outcome and therapy response in metastatic colorectal cancer.
    Barbazán J; Muinelo-Romay L; Vieito M; Candamio S; Díaz-López A; Cano A; Gómez-Tato A; Casares de Cal Mde L; Abal M; López-López R
    Int J Cancer; 2014 Dec; 135(11):2633-43. PubMed ID: 24752533
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Circulating Tumor Cell Enumeration in a Phase II Trial of a Four-Drug Regimen in Advanced Colorectal Cancer.
    Krebs MG; Renehan AG; Backen A; Gollins S; Chau I; Hasan J; Valle JW; Morris K; Beech J; Ashcroft L; Saunders MP; Dive C
    Clin Colorectal Cancer; 2015 Jun; 14(2):115-22.e1-2. PubMed ID: 25680623
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer.
    Schwartzberg LS; Rivera F; Karthaus M; Fasola G; Canon JL; Hecht JR; Yu H; Oliner KS; Go WY
    J Clin Oncol; 2014 Jul; 32(21):2240-7. PubMed ID: 24687833
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II Trial of S-1 and Oxaliplatin Plus Cetuximab for Colorectal Cancer Patients with Initially Unresectable or Not Optimally Resectable Liver Metastases (KSCC1002).
    Oki E; Emi Y; Miyamoto Y; Kabashima A; Higashi H; Ogata Y; Ikebe M; Saeki H; Tokunaga S; Shirabe K; Beppu T; Uchida S; Takatsuki M; Sakoda M; Eguchi S; Akagi Y; Kakeji Y; Baba H; Natsugoe S; Maehara Y;
    Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S1067-74. PubMed ID: 26334293
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detection of KRAS oncogene in peripheral blood as a predictor of the response to cetuximab plus chemotherapy in patients with metastatic colorectal cancer.
    Yen LC; Yeh YS; Chen CW; Wang HM; Tsai HL; Lu CY; Chang YT; Chu KS; Lin SR; Wang JY
    Clin Cancer Res; 2009 Jul; 15(13):4508-13. PubMed ID: 19549774
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic value of the combination of circulating tumor cells plus KRAS in patients with metastatic colorectal cancer treated with chemotherapy plus bevacizumab.
    Sastre J; Vidaurreta M; Gómez A; Rivera F; Massutí B; López MR; Abad A; Gallen M; Benavides M; Aranda E; Rubio ED;
    Clin Colorectal Cancer; 2013 Dec; 12(4):280-6. PubMed ID: 24012456
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Retrospective cohort study on the safety and efficacy of bevacizumab with chemotherapy for metastatic colorectal cancer patients: the HGCSG0801 study.
    Sogabe S; Komatsu Y; Yuki S; Kusumi T; Hatanaka K; Nakamura M; Kato T; Miyagishima T; Hosokawa A; Iwanaga I; Sakata Y; Asaka M
    Jpn J Clin Oncol; 2011 Apr; 41(4):490-7. PubMed ID: 21303790
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FOLFIRINOX bevacizumab is a promising therapy for chemorefractory metastatic colorectal cancer.
    Chaix M; Vincent J; Lorgis V; Ghiringhelli F
    Oncology; 2014; 87(3):148-58. PubMed ID: 25012455
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of targeted therapy with cetuximab in patients with K-ras wild-type colorectal cancer presenting with initially unresectable metastases limited to the liver in a German setting.
    Asseburg C; Frank M; Köhne CH; Hartmann JT; Griebsch I; Mohr A; Osowski U; Schulten J; Mittendorf T
    Clin Ther; 2011 Apr; 33(4):482-97. PubMed ID: 21635994
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Retrospective study as first-line chemotherapy combined anti-VEGF antibody with fluoropyrimidine for frail patients with unresectable or metastatic colorectal cancer.
    Yoshida M; Goto M; Kii T; Nishitani H; Kawabe S; Kuwakado S; Asaishi K; Miyamoto T; Higuchi K
    Digestion; 2013; 87(1):59-64. PubMed ID: 23343971
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical study of tegafur-gimeracil-oteracil potassium capsule (s-1) and oxaliplatin combination chemotherapy in advanced colorectal cancer.
    Liu H; Wang Y; Li G; Song W; Wang R
    J Cancer Res Ther; 2015; 11(2):331-5. PubMed ID: 26148595
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase II study of S-1, oxaliplatin, oral leucovorin, and bevacizumab combination therapy (SOLA) in patients with unresectable metastatic colorectal cancer.
    Nishina T; Kato T; Yamazaki K; Yoshino T; Miyata Y; Esaki T; Moriwaki T; Boku N; Hyodo I
    Cancer Chemother Pharmacol; 2015 Sep; 76(3):547-53. PubMed ID: 26198316
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study).
    Muro K; Boku N; Shimada Y; Tsuji A; Sameshima S; Baba H; Satoh T; Denda T; Ina K; Nishina T; Yamaguchi K; Takiuchi H; Esaki T; Tokunaga S; Kuwano H; Komatsu Y; Watanabe M; Hyodo I; Morita S; Sugihara K
    Lancet Oncol; 2010 Sep; 11(9):853-60. PubMed ID: 20708966
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An open-label, single-arm, phase 2 trial of panitumumab plus FOLFIRI as second-line therapy in patients with metastatic colorectal cancer.
    Cohn AL; Shumaker GC; Khandelwal P; Smith DA; Neubauer MA; Mehta N; Richards D; Watkins DL; Zhang K; Yassine MR
    Clin Colorectal Cancer; 2011 Sep; 10(3):171-7. PubMed ID: 21855038
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase II trial of S-1 monotherapy in metastatic colorectal cancer after failure of irinotecan- and oxaliplatin-containing regimens.
    Jeung HC; Rha SY; Cho BC; Yoo NC; Roh JK; Roh WJ; Chung HC; Ahn JB
    Br J Cancer; 2006 Dec; 95(12):1637-41. PubMed ID: 17106441
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.